Moneycontrol
HomeNewsBusinessMarketsFII View: Trump tariff on India relatively high but pharma exemption a relief, says LGT's Stefan Hofer
Trending Topics

FII View: Trump tariff on India relatively high but pharma exemption a relief, says LGT's Stefan Hofer

Given the policy uncertainty, LGT Bank's Stefan Hofer sees a modest upside in gold prices, predominantly as a hedge against geopolitical risk and rising inflationary pressures.

April 03, 2025 / 13:48 IST
Story continues below Advertisement
Stefan Hofer is the Chief Investment Strategist at LGT Private Banking Asia Pacific

US President Trump’s fresh tariffs are expected to have a negative impact on global trade, and the levies could hurt the global business cycle, especially in Asia, Stefan Hofer, Chief Investment Strategist at LGT Private Banking Asia Pacific has said.

"The reason being is that US is not applying punitive tariffs to China alone (at a 54% rate), but also to southeast Asian economies and Taiwan as well. This means that the transhipment of exports via third party countries will not be a viable way to circumvent tariffs destined for Chinese firm," he said in an interview to Moneycontrol.

Story continues below Advertisement

For India, Stefan Hofer is of the view that tariff at a 26% represents a relatively high rate, compared to the European Union (20%) or the United Kingdom (10%). However, it has been reported that Pharmaceuticals are exempt, which may offer India some relief, he said.

Edited excerpts: